Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
10
Date Issued
2023-04-01
Author(s)
Herbst, Roy S
Wu, Yi-Long
John, Thomas
Grohe, Christian
Majem, Margarita
Wang, Jie
Kato, Terufumi
Goldman, Jonathan W
Laktionov, Konstantin
Kim, Sang-We
Vu, Huu Vinh
Lu, Shun
Lee, Kye Young
Mukhametshina, Guzel
Akewanlop, Charuwan
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A
Urban, Damien
Huang, Xiangning
Bolanos, Ana
Stachowiak, Marta
Tsuboi, Masahiro
Abstract
The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data.
SDGs
Type
journal article